CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany

7/11/24 7:20:10 AM ET

$BNTX

$CVAC

$PFE

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BNTX alert in real time by email

New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics.
First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent litigation
UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement expected later in 2024

Get the next $BNTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BNTX
$CVAC
$PFE

Company	Date	Price Target	Rating	Analyst
BioNTech SE $BNTX	11/19/2024	$130.00	Buy	Berenberg
BioNTech SE $BNTX	11/19/2024	$110.00 → $125.00	In-line → Outperform	Evercore ISI
Pfizer Inc. $PFE	11/15/2024	$25.00	Underperform	Wolfe Research
BioNTech SE $BNTX	11/8/2024	$90.00 → $137.00	Neutral → Buy	Goldman
Pfizer Inc. $PFE	10/25/2024	$30.00	Neutral	Citigroup
Pfizer Inc. $PFE	10/17/2024	$32.00	Mkt Perform	Bernstein
BioNTech SE $BNTX	9/24/2024	$93.00 → $145.00	Equal-Weight → Overweight	Morgan Stanley
BioNTech SE $BNTX	9/17/2024	$96.00 → $150.00	Hold → Buy	Jefferies

More analyst ratings

$BNTX
$CVAC
$PFE
Leadership Updates

Live Leadership Updates

Pfizer Announces New Chief Scientific Officer and President, Research & Development
Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer Pfizer Inc. (NYSE:PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer wa
11/20/24 6:45:00 AM ET
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care
BioNTech to Acquire Biotheus to Boost Oncology Strategy
Acquisition to support the global execution of BioNTech's oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumorsWith the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinationsBioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 202
11/13/24 6:45:00 AM ET
$BNTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's
11/4/24 7:20:00 AM ET
$CVAC
Biotechnology: Pharmaceutical Preparations
Health Care

$BNTX
$CVAC
$PFE
Press Releases

Fastest customizable press release news feed in the world

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
Zai Lab (("Zai Lab", NASDAQ:ZLAB, HKEX: 9688)) and Pfizer (("Pfizer", NYSE:PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this collaboration, Zai Lab will leverage the industry-leading commercialization infrastructure of Pfizer's affiliated companies in the anti-infective therapeutic area to help accelerate access to this important therapy for patients in need in mainland China. The period of collaboration is for the imported product through Novem
11/21/24 4:00:00 AM ET
$PFE
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
Pfizer Announces New Chief Scientific Officer and President, Research & Development
Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer Pfizer Inc. (NYSE:PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer wa
11/20/24 6:45:00 AM ET
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care
European Commission Approves Pfizer's HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
In the EU, HYMPAVZI is the first once-weekly subcutaneous treatment approved for eligible people living with severe hemophilia B and the first to be administered via a pre-filled pen or syringe for people living with severe hemophilia A or B HYMPAVZI's approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with se
11/20/24 4:00:00 AM ET
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care

$BNTX
$CVAC
$PFE
Market Insights

Live Market Insights

European Commission Approves Pfizer's DURVEQTIX, A One-Time Gene Therapy For Adults With Hemophilia B
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9) after up to four years of follow-up, providing sustained bleed protection and potentially avoiding years of treatment burden with prophylaxis for many patients.Pfizer Inc. (NYSE:PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to v
7/25/24 10:52:38 AM ET
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care
Pfizer's Options: A Look at What the Big Money is Thinking
Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 21 unusual trades. Delving into the details, we found 42% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $296,355, and 18 were calls, valued at $1,032,173. Expected Price Movements Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $35.0 for Pfizer over the last 3 months. Analyzing Volume & Open Interest Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
7/25/24 10:46:09 AM ET
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Sangamo Therapeutics Inc (NASDAQ:SGMO), which developed a treatment in collaboration with Pfizer Inc (NYSE:PFE), received a boost to its stock price after struggling with liquidity issues. At last check Wednesday, Sangamo was up more than 36.2%, trading at 55 cents per share. Both companies released results from the Phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for adult patients with moderately severe to severe hemophilia A. The AFFINE study achieved its primary objective. Also Read: Second Death – Pfizer Reports Young Boy’s Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial. Following a single 3e13 vg/kg dos
7/24/24 12:10:52 PM ET
$PFE
$SGMO
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen
11/12/24 7:20:00 AM ET
$CVAC
Biotechnology: Pharmaceutical Preparations
Health Care
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse
11/7/24 7:30:00 AM ET
$CVAC
Biotechnology: Pharmaceutical Preparations
Health Care
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113 based on BioNTech's FixVac platform Initiated two Phase 2 dose optimization trials with BNT327/PM8002 in small-cell lung cancer and in triple-negative breast cancer to inform planned pivotal Phase 3 trialsPhase 2 clinical trial on track to evaluate mRNA-based individualized cancer vaccine candidate autogene cevumeran (BNT122/RO7198457) as an adjuvant treatment in patients with high-risk muscle-invasive urothelial cancerSuccessfully launched variant-adapted COVID-19 vaccines for the 2024/2025 vaccination season in multiple regionsReports
11/4/24 6:45:00 AM ET
$BNTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

October 25, 2024 - FDA Roundup: October 25, 2024
For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter
10/25/24 2:48:21 PM ET
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care
FDA Approval for HYMPAVZI issued to PFIZER INC
Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:
10/15/24 2:57:27 PM ET
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care
October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B
For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro
10/11/24 2:12:15 PM ET
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care

CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany

Chat with this insight

Recent Analyst Ratings for $BNTX$CVAC$PFE

$BNTX$CVAC$PFE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chairman & CEO Bourla Albert

SEC Form 4 filed by Executive Vice President Johnson Rady A

SEC Form 4 filed by Executive Vice President Johnson Rady A

$BNTX$CVAC$PFE Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by BioNTech SE

SEC Form SC 13D filed by BioNTech SE

SEC Form SC 13G/A filed by CureVac N.V. (Amendment)

$BNTX$CVAC$PFE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

$BNTX$CVAC$PFE Leadership Updates

Live Leadership Updates

Pfizer Announces New Chief Scientific Officer and President, Research & Development

BioNTech to Acquire Biotheus to Boost Oncology Strategy

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

$BNTX$CVAC$PFE Press Releases

Fastest customizable press release news feed in the world

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

Pfizer Announces New Chief Scientific Officer and President, Research & Development

European Commission Approves Pfizer's HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors

$BNTX$CVAC$PFE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Berenberg initiated coverage on BioNTech with a new price target

BioNTech upgraded by Evercore ISI with a new price target

Wolfe Research initiated coverage on Pfizer with a new price target

$BNTX$CVAC$PFE Market Insights

Live Market Insights

European Commission Approves Pfizer's DURVEQTIX, A One-Time Gene Therapy For Adults With Hemophilia B

Pfizer's Options: A Look at What the Big Money is Thinking

Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study

$BNTX$CVAC$PFE SEC Filings

SEC Form 6-K filed by BioNTech SE

SEC Form 6-K filed by BioNTech SE

SEC Form 6-K filed by CureVac N.V.

$BNTX$CVAC$PFE Financials

Live finance-specific insights

$BNTX$CVAC$PFE FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

October 25, 2024 - FDA Roundup: October 25, 2024

FDA Approval for HYMPAVZI issued to PFIZER INC

October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

Recent Analyst Ratings for
$BNTX
$CVAC
$PFE

$BNTX
$CVAC
$PFE
Insider Trading

$BNTX
$CVAC
$PFE
Large Ownership Changes

$BNTX
$CVAC
$PFE
Insider Purchases

$BNTX
$CVAC
$PFE
Leadership Updates

$BNTX
$CVAC
$PFE
Press Releases

$BNTX
$CVAC
$PFE
Analyst Ratings

$BNTX
$CVAC
$PFE
Market Insights

$BNTX
$CVAC
$PFE
SEC Filings

$BNTX
$CVAC
$PFE
Financials

$BNTX
$CVAC
$PFE
FDA approvals